Coptisine reverses Alzheimer’s disease by targeting cholinergic and amyloidogenic pathways

IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Medical hypotheses Pub Date : 2024-06-12 DOI:10.1016/j.mehy.2024.111407
Abhideep Roy , Rubina Roy , Bhagwan Sahay Meena , Diwakar Kumar , Pallab Bhattacharya , Indira Gahatraj , Sushila Chhetry , Anupom Borah
{"title":"Coptisine reverses Alzheimer’s disease by targeting cholinergic and amyloidogenic pathways","authors":"Abhideep Roy ,&nbsp;Rubina Roy ,&nbsp;Bhagwan Sahay Meena ,&nbsp;Diwakar Kumar ,&nbsp;Pallab Bhattacharya ,&nbsp;Indira Gahatraj ,&nbsp;Sushila Chhetry ,&nbsp;Anupom Borah","doi":"10.1016/j.mehy.2024.111407","DOIUrl":null,"url":null,"abstract":"<div><p>Alzheimer’s disease (AD) is one of the most unanswered diseases in the world as its complicated pathological mechanism makes it a formidable challenge in modern healthcare with limited intervention options. Due to its chronic nature in neurodegeneration, leading to cognitive decline and brain damage, mitigating this disease is now of major concern globally. The revelation of certain key hallmarks of AD pathology such as cholinergic dysfunction and amyloid plaque toxicity has thrown some insight into identifying therapeutic targets. Only symptomatic relief has been achieved by a single-target therapeutic approach, thus, the development of multi-impediment drugs is urgently needed. The adverse effects of current AD medication and repeated failure of futuristic drugs led us to hunt for a natural compound with beneficial properties that can target multi-facets of AD pathology, and cure this devastating brain disorder. The hypothesis of targeting different pathways contributing to progressive neurodegeneration in AD pathophysiology can be considered a new-age intervention. Coptisine, a bioactive alkaloid with benzyl tetrahydroisoquinoline in structure possesses enormous pharmacological benefits including neuroprotective abilities. Together with the potential of coptisine to inhibit the major targets of AD pathogenesis namely acetylcholinesterase (AChE), beta-secretase (BACE1), and gamma-secretase, this alkaloid can emerge as a new-age multi-target therapeutic for AD. However, robust research on coptisine’s suitability against AD pathogenesis is pivotal considering its therapeutic promises and an unambiguous understanding of the coptisine’s future can be predicted by evaluating its efficacy and safety for ameliorating AD.</p></div>","PeriodicalId":18425,"journal":{"name":"Medical hypotheses","volume":"189 ","pages":"Article 111407"},"PeriodicalIF":2.1000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical hypotheses","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0306987724001506","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Alzheimer’s disease (AD) is one of the most unanswered diseases in the world as its complicated pathological mechanism makes it a formidable challenge in modern healthcare with limited intervention options. Due to its chronic nature in neurodegeneration, leading to cognitive decline and brain damage, mitigating this disease is now of major concern globally. The revelation of certain key hallmarks of AD pathology such as cholinergic dysfunction and amyloid plaque toxicity has thrown some insight into identifying therapeutic targets. Only symptomatic relief has been achieved by a single-target therapeutic approach, thus, the development of multi-impediment drugs is urgently needed. The adverse effects of current AD medication and repeated failure of futuristic drugs led us to hunt for a natural compound with beneficial properties that can target multi-facets of AD pathology, and cure this devastating brain disorder. The hypothesis of targeting different pathways contributing to progressive neurodegeneration in AD pathophysiology can be considered a new-age intervention. Coptisine, a bioactive alkaloid with benzyl tetrahydroisoquinoline in structure possesses enormous pharmacological benefits including neuroprotective abilities. Together with the potential of coptisine to inhibit the major targets of AD pathogenesis namely acetylcholinesterase (AChE), beta-secretase (BACE1), and gamma-secretase, this alkaloid can emerge as a new-age multi-target therapeutic for AD. However, robust research on coptisine’s suitability against AD pathogenesis is pivotal considering its therapeutic promises and an unambiguous understanding of the coptisine’s future can be predicted by evaluating its efficacy and safety for ameliorating AD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
科普替辛通过靶向胆碱能和淀粉样蛋白生成途径逆转阿尔茨海默病
阿尔茨海默病(AD)是世界上最悬而未决的疾病之一,其复杂的病理机制使其成为现代医疗保健领域的一项艰巨挑战,而且干预方案有限。由于这种疾病具有神经变性的慢性性质,会导致认知能力下降和脑损伤,因此缓解这种疾病目前已成为全球关注的主要问题。胆碱能功能障碍和淀粉样斑块毒性等注意力缺失症病理特征的揭示,为确定治疗靶点提供了一些启示。单靶点治疗方法只能缓解症状,因此迫切需要开发多靶点药物。目前的抗多发性硬化药物的不良反应和未来药物的屡次失败,促使我们开始寻找一种具有有益特性的天然化合物,它可以针对多方面的多发性硬化病理,治疗这种破坏性的脑部疾病。针对导致渐进性神经退行性疾病病理生理学的不同途径的假说可被视为一种新时代的干预措施。Coptisine 是一种具有生物活性的生物碱,其结构为苄基四氢异喹啉,具有巨大的药理作用,包括神经保护能力。再加上黄连碱具有抑制乙酰胆碱酯酶(AChE)、β-分泌酶(BACE1)和γ-分泌酶等导致注意力缺失症发病的主要靶点的潜力,因此这种生物碱可以作为一种新时代的多靶点注意力缺失症治疗药物出现。然而,考虑到其治疗前景,对 coptisine 针对 AD 发病机制的适用性进行强有力的研究至关重要,通过评估其对改善 AD 的疗效和安全性,可以对 coptisine 的未来有一个明确的认识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medical hypotheses
Medical hypotheses 医学-医学:研究与实验
CiteScore
10.60
自引率
2.10%
发文量
167
审稿时长
60 days
期刊介绍: Medical Hypotheses is a forum for ideas in medicine and related biomedical sciences. It will publish interesting and important theoretical papers that foster the diversity and debate upon which the scientific process thrives. The Aims and Scope of Medical Hypotheses are no different now from what was proposed by the founder of the journal, the late Dr David Horrobin. In his introduction to the first issue of the Journal, he asks ''what sorts of papers will be published in Medical Hypotheses? and goes on to answer ''Medical Hypotheses will publish papers which describe theories, ideas which have a great deal of observational support and some hypotheses where experimental support is yet fragmentary''. (Horrobin DF, 1975 Ideas in Biomedical Science: Reasons for the foundation of Medical Hypotheses. Medical Hypotheses Volume 1, Issue 1, January-February 1975, Pages 1-2.). Medical Hypotheses was therefore launched, and still exists today, to give novel, radical new ideas and speculations in medicine open-minded consideration, opening the field to radical hypotheses which would be rejected by most conventional journals. Papers in Medical Hypotheses take a standard scientific form in terms of style, structure and referencing. The journal therefore constitutes a bridge between cutting-edge theory and the mainstream of medical and scientific communication, which ideas must eventually enter if they are to be critiqued and tested against observations.
期刊最新文献
Hypothesis: Waterfowl may be important intermediary reservoirs of Naegleria fowleri Miller Fisher’s telephone effect is a consequence of generative rationality Editorial Board Could systemic infections influence the effectiveness of deep brain stimulation therapy in patients with dystonia? Cochlear origin of tinnitus and outer hair cell motor protein Prestin as a biomarker for tinnitus
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1